Hodgkin Lymphoma, Adult
18
6
7
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
5.6%
1 terminated out of 18 trials
80.0%
-6.6% vs benchmark
6%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (18)
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Physical Capacity in Hodgkin Lymphoma Survivors
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Compassionate Use Re-Infusion of ATLCAR.CD30
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy